Evidence map›Paper›PMID 38649648›Full record

SynthesisInternational journal of clinical oncology2024

Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.

Tetsuhiro Yoshinami, Kazuki Nozawa, Takamichi Yokoe, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano and 17 more

Abstract readSystematic ReviewMeta-AnalysisComparative Study
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Temporal trends in time toxicity of R-CHOP: a nationwide hospital-based database analysis in Japan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 17 institutions in 1 country.

Tetsuhiro YoshinamiDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. yosinami-te@onsurg.med.osaka-u.ac.jp.
Kazuki NozawaDepartment of Center for Cancer Genomics and Advanced Therapeutics, Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
Takamichi YokoeDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Yukinori OzakiDepartment of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Hiroshi NishioDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Kenji TsuchihashiDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University, Fukuoka, Japan.
Eiki IchiharaCenter for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
Yuji MiuraDepartment of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Makoto EndoDepartment of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.
Shingo YanoDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Dai MaruyamaDepartment of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Nobuyuki SusumuDepartment of Obstetrics and Gynecology, International University of Health and Welfare Narita Hospital, Chiba, Japan.
Munetaka TakekumaDeparment of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
Takashi MotohashiDepartment of Obstetrics and Gynecology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
Mamoru ItoDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University, Fukuoka, Japan.
Eishi BabaDepartment of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Nobuaki OchiDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Toshio KuboDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Keita UchinoDepartment of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan.
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Yutaro KamiyamaDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan.
Shinji NakaoDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
Shinobu TamuraDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Hitomi NishimotoDepartment of Nursing, Okayama University Hospital, Okayama, Japan.
Yasuhisa KatoDepartment of Drug Information, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Kanagawa, Japan.
Atsushi SatoDepartment of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Toshimi TakanoDepartment of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Kyushu University · JPJapanese Foundation For Cancer Research · JPJikei University School of Medicine · JPOkayama University Hospital · JPKeio University · JPAichi Cancer Center · JPHirosaki University · JPInternational University of Health and Welfare · JPKanazawa University · JPKawasaki Medical School · JPNTT Medical Center · JPOsaka University · JPShizuoka Cancer Center · JPShonan University of Medical Sciences · JPTokyo Women's Medical University Hospital · JPToranomon Hospital · JPWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroudGranulocyte colony-stimulating factor (G-CSF) is widely used for the primary prophylaxis of febrile neutropenia (FN). Two types of G-CSF are available in Japan, namely G-CSF chemically bound to polyethylene glycol (PEG G-CSF), which provides long-lasting effects with a single dose, and non-polyethylene glycol-bound G-CSF (non-PEG G-CSF), which must be sequentially administrated for several days.

methodsThis current study investigated the utility of these treatments for the primary prophylaxis of FN through a systematic review of the literature. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis or meta-analysis was conducted to evaluate six outcomes.

resultsThrough the first and second screenings, 23 and 18 articles were extracted for qualitative synthesis and meta-analysis, respectively. The incidence of FN was significantly lower in the PEG G-CSF group than in the non-PEG G-CSF group with a strong quality/certainty of evidence. The differences in other outcomes, such as overall survival, infection-related mortality, the duration of neutropenia (less than 500/μL), quality of life, and pain, were not apparent.

conclusionsA single dose of PEG G-CSF is strongly recommended over multiple-dose non-PEG G-CSF therapy for the primary prophylaxis of FN.

Indexed as

Granulocyte Colony-Stimulating FactorPolyethylene GlycolsFebrile NeutropeniaHumansPractice Guidelines as TopicRecombinant ProteinsGranulocyte Colony-Stimulating Factorpegylated granulocyte colony-stimulating factorPolyethylene GlycolsRecombinant ProteinsMeta-analysisMultiple dosesNon-PEG G-CSFPEG G-CSFSingle dose

Identifiers

PMID38649648
OpenAlexW4395046443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.